Organizer(s): David Komander and Sylvie UrbéDate: January 28 - February 01, 2018
Location: Granlibakken Tahoe, Tahoe City, CA, USA
These are exciting times for ubiquitin research: potential targets for small molecule inhibitors are emerging in a variety of human diseases and being exploited by the pharmaceutical industry. At the same time, new enzymes regulating ubiquitin modifications are still being discovered, and the complexity of ubiquitin modifications continues to increase with the emerging cross-talk between post-translational modifications. This conference will focus on the latest insights in the large area of cellular regulation mediated by ubiquitin and ubiquitin-like modifiers. Key goals are to provide overviews and updates on emerging frontiers, and encourage efforts to exploit the ubiquitin system to provide new treatments for human diseases. Rather than being organized around key enzymes in the cascade, sessions will focus on biological areas, ensuring a balanced mix of mechanistic and physiology aspects. The meeting will feature both key opinion leaders on ubiquitination who are known to present unpublished results and leading researchers from peripheral fields who will contribute new ideas. A short selection of company-associated academic speakers will provide insights into the translational opportunities in this area.
Scholarship Deadline: October 2 2017
Discounted Abstract Deadline: October 2 2017
Abstract Deadline: October 31 2017
Discounted Registration Deadline: December 1 2017
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: